Natera (NASDAQ:NTRA) Insider John Fesko Sells 781 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 781 shares of the firm’s stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $406.00, for a total value of $317,086.00. Following the completion of the sale, the insider directly owned 196,476 shares of the company’s stock, valued at approximately $79,769,256. This represents a 0.40% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Wednesday, October 28th, John Fesko sold 898 shares of Natera stock. The stock was sold at an average price of $426.34, for a total value of $382,853.32.
• On Monday, August 10th, John Fesko sold 6,517 shares of Natera stock. The shares were sold at an average price of $321.53, for a total transaction of $2,095,411.01.
• On Monday, August 3rd, John Fesko sold 295 shares of Natera stock. The shares were sold at an average price of $267.99, for a total transaction of $79,057.05.

Natera Stock Up 2.7%

Shares of Natera stock opened at $436.00 on Friday. The firm has a market capitalization of $62.85 billion, a P/E ratio of -320.59 and a beta of 1.50. The company has a 50 day moving average price of $375.27 and a 200 day moving average price of $265.54. Natera, Inc. has a 52 week low of $181.00 and a 52 week high of $437.41.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. Natera’s revenue was up 37.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.74) EPS. As a group, research analysts anticipate that Natera, Inc. will post -1.14 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Thursday, October 15th. TD Cowen upped their target price on Natera from $340.00 to $480.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. Roth Capital initiated coverage on Natera in a research report on Thursday, October 22nd. They issued a “buy” rating and a $475.00 target price on the stock. Rothschild & Co Redburn initiated coverage on Natera in a research note on Tuesday, September 8th. They issued a “buy” rating and a $385.00 target price for the company. Finally, Canaccord Genuity Group lifted their price target on Natera from $375.00 to $500.00 and gave the stock a “buy” rating in a research report on Monday, October 19th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and a consensus price target of $394.31.

Institutional Investors Weigh In On Natera

Large investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in Natera during the 2nd quarter valued at approximately $2,962,770,000. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Natera by 1.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock valued at $238,334,000 after acquiring an additional 11,793 shares during the last quarter. Maverick Capital Ltd. boosted its holdings in shares of Natera by 24.1% in the 1st quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock valued at $234,315,000 after acquiring an additional 227,605 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Natera by 10.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock worth $226,220,000 after acquiring an additional 80,440 shares during the period. Finally, Bank of America Corp DE acquired a new stake in shares of Natera in the second quarter worth $199,960,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.